NO334819B1 - Anvendelse av hydroksysteroider og farmasøytisk akseptable salter og estere derav, for fremstilling av et medikament for beskyttelse mot iskemisk skade på perifere organer - Google Patents

Anvendelse av hydroksysteroider og farmasøytisk akseptable salter og estere derav, for fremstilling av et medikament for beskyttelse mot iskemisk skade på perifere organer Download PDF

Info

Publication number
NO334819B1
NO334819B1 NO20041057A NO20041057A NO334819B1 NO 334819 B1 NO334819 B1 NO 334819B1 NO 20041057 A NO20041057 A NO 20041057A NO 20041057 A NO20041057 A NO 20041057A NO 334819 B1 NO334819 B1 NO 334819B1
Authority
NO
Norway
Prior art keywords
group
carbon atoms
groups
atoms
hydroxy
Prior art date
Application number
NO20041057A
Other languages
English (en)
Norwegian (no)
Other versions
NO20041057L (no
Inventor
Ernst Wülfert
Original Assignee
Hunter Fleming Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hunter Fleming Ltd filed Critical Hunter Fleming Ltd
Publication of NO20041057L publication Critical patent/NO20041057L/no
Publication of NO334819B1 publication Critical patent/NO334819B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20041057A 2001-08-14 2004-03-12 Anvendelse av hydroksysteroider og farmasøytisk akseptable salter og estere derav, for fremstilling av et medikament for beskyttelse mot iskemisk skade på perifere organer NO334819B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0119810A GB2378898A (en) 2001-08-14 2001-08-14 Prophylactic and therapeutic use of hydroxysteroids
PCT/GB2002/003770 WO2003015791A1 (en) 2001-08-14 2002-08-13 Phophylactic and therapeutic use of hydroxysteroids

Publications (2)

Publication Number Publication Date
NO20041057L NO20041057L (no) 2004-03-12
NO334819B1 true NO334819B1 (no) 2014-06-10

Family

ID=9920376

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20041057A NO334819B1 (no) 2001-08-14 2004-03-12 Anvendelse av hydroksysteroider og farmasøytisk akseptable salter og estere derav, for fremstilling av et medikament for beskyttelse mot iskemisk skade på perifere organer

Country Status (19)

Country Link
US (1) US8148355B2 (enExample)
EP (1) EP1416937B1 (enExample)
JP (1) JP4541698B2 (enExample)
KR (1) KR100895281B1 (enExample)
CN (1) CN1700920B (enExample)
AT (1) ATE429919T1 (enExample)
AU (1) AU2002321472B2 (enExample)
CA (1) CA2457050C (enExample)
CY (1) CY1109233T1 (enExample)
DE (1) DE60232154D1 (enExample)
DK (1) DK1416937T3 (enExample)
ES (1) ES2324859T3 (enExample)
GB (1) GB2378898A (enExample)
IL (2) IL160362A0 (enExample)
NO (1) NO334819B1 (enExample)
NZ (1) NZ531100A (enExample)
PT (1) PT1416937E (enExample)
RU (1) RU2329049C2 (enExample)
WO (1) WO2003015791A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0409498D0 (en) * 2004-04-28 2004-06-02 Hunter Fleming Ltd Transdermal steroid formulation
US7910755B2 (en) 2004-09-29 2011-03-22 Harbor Biosciences, Inc. Stem cell expansion and uses
GB0623971D0 (en) * 2006-11-30 2007-01-10 Hunter Fleming Ltd Modulation of prostaglandin/cyclooxygenase metabolic pathways
KR20090086272A (ko) * 2006-11-30 2009-08-11 헌터-플레밍 리미티드 프로스타글란딘／시클로옥시게나제 대사 경로의 조절
EP2653163A1 (en) * 2012-04-19 2013-10-23 Université de Liège Estrogenic components for use in the treatment of neurological disorders
CN105078954A (zh) * 2015-08-20 2015-11-25 南京华宽信息咨询中心 一种治疗急性肾衰药物及其应用
CN105168197A (zh) * 2015-08-22 2015-12-23 南京华宽信息咨询中心 一种治疗肾功能不全药物及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5686438A (en) * 1993-03-09 1997-11-11 University Of Utah Research Foundation Methods for preventing progressive tissue necrosis, reperfusion injury, bacterial translocation and adult respiratory distress syndrome
ATE283052T1 (de) * 1993-03-09 2004-12-15 Univ Utah Res Found Verwendung von dhea oder dessen derivate zur herstellung eines medikaments zur vorbeugung von progressiver gewebe-nekrose, reperfusionsschädigung, bakterieller translokation und vom atemnotsyndrom bei erwachsenen
US5846963A (en) * 1995-06-07 1998-12-08 University Of Utah Research Foundation Methods for preventing progressive tissue necrosis, reperfusion injury, bacterial translocation and adult respiratory distress syndrome
US5753640A (en) * 1995-06-07 1998-05-19 University Of Utah Research Foundation Methods for preventing progressive tissue necrosis, reperfusion injury, bacterial translocation and adult respiratory distress syndrome
US5977095A (en) * 1993-03-09 1999-11-02 University Of Utah Research Foundation Methods for preventing progressive tissue necrosis, reperfusion injury, bacterial translocation and respiratory distress syndrome
IT1282289B1 (it) * 1995-06-23 1998-03-16 Sigma Tau Ind Farmaceuti 17-idrossiimminoalchil e 17-idrossiimminometilalchenil ciclopentaperidrofenantreni attivi sul sistema cardiovascolare,
WO1999011271A1 (en) * 1997-08-29 1999-03-11 Dalhousie University Use of polycyclic steroid compounds for the manufacture of a medicament for the treatment of cystic kidney diseases, vascular infarction, uremia and related conditions
AU3467699A (en) * 1998-04-14 1999-11-01 Pharmadigm, Inc. Method for reducing central nervous system impairment
GB0003524D0 (en) * 2000-02-15 2000-04-05 Btg Int Ltd Cytoprotective steroids (II)
GB2363984A (en) * 2000-06-29 2002-01-16 Hunter Fleming Ltd Protection against neuronal damage using 3-hydroxy-7 -hydroxy steroids and 3-oxo-7 -hydroxy steroids
GB2363983A (en) * 2000-06-29 2002-01-16 Hunter Fleming Ltd Protection against neuronal damage using 7-hydroxyepiandrosterone

Also Published As

Publication number Publication date
KR20040041577A (ko) 2004-05-17
RU2329049C2 (ru) 2008-07-20
CA2457050A1 (en) 2003-02-27
JP2005506321A (ja) 2005-03-03
CN1700920A (zh) 2005-11-23
EP1416937B1 (en) 2009-04-29
AU2002321472B2 (en) 2007-11-08
EP1416937A1 (en) 2004-05-12
US8148355B2 (en) 2012-04-03
KR100895281B1 (ko) 2009-04-29
ES2324859T3 (es) 2009-08-18
IL160362A0 (en) 2004-07-25
DK1416937T3 (da) 2009-08-24
NO20041057L (no) 2004-03-12
HK1065703A1 (en) 2005-03-04
DE60232154D1 (de) 2009-06-10
RU2004104362A (ru) 2005-05-10
GB2378898A (en) 2003-02-26
WO2003015791A1 (en) 2003-02-27
JP4541698B2 (ja) 2010-09-08
US20040248868A1 (en) 2004-12-09
CA2457050C (en) 2010-10-12
PT1416937E (pt) 2009-07-24
CY1109233T1 (el) 2014-07-02
NZ531100A (en) 2006-02-24
IL160362A (en) 2011-10-31
ATE429919T1 (de) 2009-05-15
GB0119810D0 (en) 2001-10-10
CN1700920B (zh) 2012-05-30

Similar Documents

Publication Publication Date Title
US20100130459A1 (en) Neuroprotective 7-beta-hydroxysteroids
CN1853637B (zh) 五环三萜类化合物作为糖原磷酸化酶抑制剂的制药用途
NO328598B1 (no) Benzopyran-inneholdende forbindelser, anvendelse av samme for fremstilling av medikament samt farmasoytisk sammensetning innbefattende det samme
US8148355B2 (en) Phophylactic and therapeutic use of hydroxysteroids
JP7421815B2 (ja) 心不全の治療のための１７ベータ－複素環ジギタリス類似化合物
AU2002321472A1 (en) Phophylactic and therapeutic use of hydroxysteroids
NO327959B1 (no) Anvendelse av 7-hydroksyepiandrosteron for fremstilling av et medikament for beskyttelse mot akutt eller kronisk nevronskade
HK1065703B (en) Prophylactic and therapeutic use of hydroxysteroids
MXPA94007369A (en) Novel deoxy and oxygen-substituted sugar-containing 14-aminosteroid compounds
JPWO1999039719A1 (ja) 虚血再灌流障害予防および治療剤

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees